Jim Bishop joined Avalyn as senior vice president, business operations in 2023, prior to which he was senior vice president, business operations of Enzyvant Therapeutics. Mr. Bishop previously held the role of senior vice president, business operations at Altavant Sciences where he led the integration and restructuring of the combination of Enzyvant and Altavant Sciences.
Earlier in his career, Mr. Bishop served in business development, operations and project management roles at multiple biotechnology and pharmaceutical companies including Roivant Sciences, Teva Pharmaceuticals, Cabernet Pharmaceuticals and Oxygen Biotherapeutics. He began his career as a scientist at GlaxoSmithKline. Mr. Bishop earned an MBA from Meredith College and a Bachelor of Science in Biochemistry from Pennsylvania State University.